Investigational drug · Phase 2
Benmelstobart
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alveolar Soft Part Sarcoma, Non-Small Cell Lung Cancer, Gastroesophageal Adenocarcinoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
44
Any phase or sponsor naming "Benmelstobart"
First trial start
2023
Jul 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Benmelstobart", any sponsor or status.
- Phase 234
Conditions studied
As listed on its trial records.
- Alveolar Soft Part Sarcoma
- Non-Small Cell Lung Cancer
- Gastroesophageal Adenocarcinoma
- Malignant Neoplasms of Digestive Organs
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Sarcoma · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Benmelstobart" as an intervention, largest first.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
LaNova Medicines Zhejiang Co., Ltd.Industry
NCT05934331 · 632 participants (planned) · Start Jul 27, 2023 · Primary completion Aug 6, 2031
Drug: LM-302; Toripalimab and 9 more · For: Malignant Neoplasms of Digestive Organs
Sites: Shanghai, China
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaPivotal-lookingNot yet recruiting
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT07446335 · 578 participants (planned) · Start Apr 2026 · Primary completion Dec 2028
Drug: anlotinib combined with benmelstobart; Toripalimab Combined with Chemotherapy · For: Advanced Esophageal Squamous Cell Carcinoma
Sites: Zhengzhou, China
- Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal CarcinomaPivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07385079 · 412 participants (planned) · Start Mar 1, 2026 · Primary completion Jan 1, 2028
Drug: Anlotinib Hydrochloride Capsules; Gemcitabine (GEM) and 2 more · For: Nasopharyngeal Cancinoma (NPC); Nasopharyngeal Cancer
- Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell CarcinomaPivotal-lookingNot yet recruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityAcademic, hospital or other
NCT07535567 · 386 participants (planned) · Start May 5, 2026 · Primary completion Dec 31, 2028
Drug: Nimotuzumab; Nimotuzumab, Benmelstobart · For: Head and Neck Squamous Cell Carcinoma
- Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityAcademic, hospital or other
NCT07445048 · 370 participants (planned) · Start Mar 4, 2026 · Primary completion Mar 5, 2028
Drug: Bemcentinib; Nimotuzumab · For: Head & Neck Squamous Cell Carcinoma; Head & Neck Cancer; Postoperative Adjuvant Treatment
Sites: Shanghai, China
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT06953843 · 366 participants (planned) · Start Jul 9, 2025 · Primary completion Jun 30, 2027
Drug: Benmelstobart combined with chemotherapy; Benmelstobart combined with chemotherapy and 4 more · For: NSCLC Stage IV Without EGFR/ALK Mutation
Sites: Chongqing, China
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsPivotal-lookingNot yet recruiting
The First Affiliated Hospital of Guangzhou Medical UniversityAcademic, hospital or other
NCT06955325 · 270 participants (planned) · Start May 2025 · Primary completion Dec 2030
Drug: Icotinib; Rezivertinib and 2 more · For: Non-Small Cell Lung Cancer
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT06496490 · 270 participants (planned) · Start Aug 6, 2024 · Primary completion Jun 2026
Drug: TQB2102 for injection; TQB2102 for injection combined with Benmelstobart injection · For: Non-Small Cell Lung Cancer
Sites: Fuzhou, China; Foshan, China; Guangzhou, China · 25 sites in all
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07371663 · 266 participants (planned) · Start Dec 3, 2025 · Primary completion Sep 30, 2028
Drug: TCC1727 tablet 90mg; TCC1727 tablet 120mg and 1 more · For: Solid Cancers; NSCLC (Advanced Non-small Cell Lung Cancer); Gastric (Stomach) Cancer and 2 more
Sites: Beijing, China; Zhengzhou, China; Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Benmelstobart Plus Anlotinib in Advanced Endometrial Cancer: Results of a Multi-Cohort, Phase II Study (ETER200).
Liang S, Chen X, Wang K, et al. · MedComm (2020) 2026
- Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.
Ji Y, Li Q, Chen L, et al. · JAMA Oncol 2026
- Efficacy and safety of induction benmelstobart plus anlotinib and chemotherapy followed by concurrent chemoradiotherapy and benmelstobart consolidation versus concurrent chemoradiotherapy followed by benmelstobart consolidation in patients with unresectable stage III NSCLC: a randomized, controlled, multicenter phase II trial protocol (BEAM-LUNG).
Song Z, Ma S, Zhang X, et al. · Front Immunol 2026
- Efficacy and safety of first-line immunotherapy-related induction and maintenance therapy for extensive-stage small cell lung cancer: a systematic review and Bayesian network meta-analysis.
Yu HJ, Liu JC, Zhang DS, et al. · Front Pharmacol 2026
- The Transition From Sunitinib Monotherapy to Modern First-Line Tyrosine Kinase Inhibitor (TKI)-Containing Regimens in Metastatic Clear-Cell Renal Cell Carcinoma.
Manda S, Singh S · Cureus 2026
- Efficacy and safety of first-line immunotherapy in advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen G, Jin Y, Su T · Transl Androl Urol 2026
Also in development for Alveolar Soft Part Sarcoma
- Anlotinib hydrochlorideAL3818, CatequentenibPhase 312 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Alveolar Soft Part Sarcoma, Metastatic Colorectal Cancer, Endometrial Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.